Emerging data from AAN 2026 across neuroimmunology, epilepsy, neuromuscular disease, movement disorders and neuroinfectious disease highlighted the continued evolution of neurology toward more precise, personalized and mechanism-driven care.
The American Academy of Neurology (AAN) Annual Meeting, Chicago, IL, USA, from April 18–22, 2026, showcased a broad range of important clinical and scientific developments. From advances in diagnosis and disease monitoring to novel therapeutic strategies and late-breaking clinical trial data, the meeting provided new insights into some of the most challenging areas of neurological practice.
To explore some of the most significant developments presented at this year’s meeting, touchNEUROLOGY spoke with leading experts from across the field. In these interviews, faculty discuss the latest clinical trial results, diagnostic innovations, evolving treatment paradigms and future directions for research and patient care.
Explore our AAN 2026 interview series below:
- Isaac Thorman and Prof. Fawaz Al-Mufti discuss GLP-1 therapies and cognitive impairment, showing new data showing a possible ‘survival paradox’
- Dr Yair Mina discusses NT-I7 in progressive multifocal leukoencephalopathy
- Prof. Peter Hedera shares insights from the Phase 3 FoCus trial in neurologic Wilson disease
- Dr Aravindhan Veerapandiyan shared the findings from the HOPE-3 phase 3 trial on upper limb function and cardiac outcomes in Duchenne muscular dystrophy
- Dr Matteo Gastaldi highlighted how the multicenter evaluation of the iDOT AQP4 assay will improve access to NMOSD diagnosis
- Jacqueline French shared the phase 3 X-TOLE2 results and the future of KV7-targeted therapy in focal epilepsy
- Prof. Michael Levy shared the phase 3 METEOROID trial data investigating satralizumab in MOGAD
- AAN 2026 late-breaking science: Key neurology trial data and clinical insights
Together, these discussions provide expert perspectives on some of the most exciting developments presented at AAN 2026 and offer insight into how emerging evidence may influence future clinical practice across neurology.
View specialities list for more content
Cite: AAN 2026 highlights: Key advances shaping the future of neurology. touchNEUROLOGY. 24 March 2026.
Editor: Katey Gabrysch, Editorial Director.
Disclosures: See individual Q&As
The content was developed and edited by human editors. No fees or funding were associated with its publication. touchNEUROLOGY utilize AI as an editorial tool (ChatGPT (GPT-4o) [Large language model]. https://chat.openai.com/chat).
This content has been developed independently by Touch Medical Media for touchNEUROLOGY. Views expressed are the speaker’s own and do not necessarily reflect the views of Touch Medical Media.
SIGN UP to touchNEUROLOGY!
Join our global community today for access to thousands of peer-reviewed articles, expert insights, and learn-on-the-go education across 150+ specialties, plus concise email updates and newsletters so you never miss out.
